ReviewFrontiers in immunology2026
Extracellular vesicles at the periodontal immune-regenerative interface: coupled mechanisms and translational challenges.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Periodontitis is a chronic immune-inflammatory disease in which dysbiotic microbial communities and sustained host responses disrupt the gingiva, periodontal ligament (PDL), cementum, and alveolar bone. Because these tissues form an integrated attachment apparatus, effective regeneration requires coordinated control of inflammation and reconstruction of soft and mineralized tissues. Extracellular vesicles (EVs) function as intercellular mediators at this immune-regenerative interface by transferring proteins, lipids, and nucleic acids among immune, stromal, vascular, and bone-remodeling cells. This review synthesizes how EVs connect immune reprogramming, microenvironmental remodeling, and tissue-specific repair in periodontitis. Across experimental studies, EVs regulate macrophage activation and T-cell balance, modulate inflammatory, oxidative, vascular, and osteoclastogenic signaling, and influence the survival, migration, and differentiation of gingival, PDL, cementoblast, and osteoblast-lineage cells. Together, these actions link inflammatory resolution to the cellular processes required for gingival healing, alveolar bone formation, cementogenesis, and re-establishment of the PDL-cementum-bone interface. EV activity is shaped by donor-cell identity and physiological state, culture and separation procedures, molecular cargo, dose, recipient cell, and disease context; this context dependence explains why different EV preparations can produce reparative or pathogenic responses. Cargo engineering, surface modification, and biomaterial-assisted local delivery offer routes to enhance potency, cellular interaction, and retention within periodontal defects. Translation now depends on defining reproducible EV products, establishing mechanism-linked potency assays, standardizing dose and quality control, and evaluating safety and function in disease-relevant models. Current evidence is predominantly preclinical and indicates that process-defined EV preparations can link inflammatory resolution with tissue reconstruction as adjuncts to infection control and established periodontal regenerative procedures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.